Program | Target | Indication | Stage | Key Highlights
UF-Kure19 | CD19 | Non-Hodgkin’s Lymphoma | Phase 1 Completed (US) | 88% CR rate; minimal CRS/ICANS; scalable validated manufacturing UF-Kure-BCMA | BCMA | Multiple Myeloma | IND-Cleared (FDA 2025) | Phase 1 start 2025 Solid Tumors | Preclinical | Tumor-specific targeting with potent in vivo efficacy